Busulphan

Acute Leukemia

Sawa Ito, MDPhase 4 / ApprovedActive

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 60/ 100
Competitive Position: 73/ 100

Competitive context

59 Active assets in the Acute Leukemia cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Sawa Ito, MD	Phase 2/3	BB
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Cytosin-Arabinosid Janssen Research & Development, LLC	Phase 2/3	BB
METHOTREXATE SWOG Cancer Research Network	Phase 3	BB
ETOPOSIDE Nanfang Hospital, Southern Medical University	Phase 2/3	BB

View all 50 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant

BBB

Indicative ·

77 / 100

myelodysplastic/myeloproliferative neoplasmDormant

BBB

Indicative ·

76 / 100

graft versus host diseaseDormant

BBB

Indicative ·

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.